Gilman Wong - Sirtex Medical CEO, Managing Director and Executive Director

SRX -- Australia Stock  

AUD 33.55  0.00  0.00%

  CEO
Mr. Gilman Wong was Chief Executive Officer Managing Director and Executive Director of the Company. Mr Wong was appointed Chief Executive Officer in May 2005 and director in June 2005. Mr Wong previously held CEO and senior executive positions in various industries. He has a strong planning and sales and marketing background.
Age: 65  CEO Since 2014      
61 2 9964 8400  http://www.sirtex.com
Wong previously held CEO and senior executive positions in the commercial and industry sector including 10 years with Email Limited. He has planning and sales and marketing background.

Management Efficiency

The company has return on total asset (ROA) of 17.25 % which means that it generated profit of $17.25 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 26.87 % meaning that it generated $26.87 on every $100 dollars invested by stockholders.

Entity Summary

Sirtex Medical Limited, a life-sciences company, develops and delivers oncology treatments using novel small particle technology in the Asia-Pacific, Europe, the Middle East, Africa, and North and South America. As of September 20, 2018, Sirtex Medical Limited operates as a subsidiary of CDH Genetech Limited. Sirtex Medical operates under Biotechnology classification in Australia and is traded on Australian Securities Exchange.Sirtex Medical Limited (SRX) is traded on Australian Securities Exchange in Australia and employs 292 people.

Sirtex Medical Leadership Team

Darren Smith, CFO, Company Secretary
Richard Hill, Non-Executive Chairman of the Board
Neville Mitchell, Independent Non-Executive Director
Gilman Wong, CEO, Managing Director and Executive Director
Tom Duthy, Global Investor Relations Manager
Michael Mangano, President of Americas Region
Katherine Woodthorpe, Non-Executive Independent Director
Nigel Lange, CEO of Europe
John Eady, Non-Executive Deputy Chairman of the Board
Anthony Dixon, Executive Vice President of Sales and Marketing,EMEA
Robert Hardie, Global Head of Operations
Helen Kurincic, Independent Non-Executive Director
Kevin Richardson, CEO, Americas
Rueben Teo, CEO, Asia Pacific (APAC)
David Cade, Global Medical Director
Andrew McLean, CEO, Executive Director
Grant Boyce, Non-Executive Director

Stock Performance Indicators

Current Sentiment - SRX

Sirtex Medical Investor Sentiment

Most of Macroaxis users are at this time bullish on Sirtex Medical Limited. What is your outlook on investing in Sirtex Medical Limited? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip
Currently Active Assets on Macroaxis
TRP   
Purchased over 40 shares of
2 days ago
Traded for 66.04
GM   
Purchased over 70 shares of
2 days ago
Traded for 36.92
V   
Purchased few shares of
2 days ago
Traded for 173.44
V   
Purchased few shares of
2 days ago
Traded for 173.44
GM   
Purchased over 70 shares of
2 days ago
Traded for 36.92
Also please take a look at World Market Map. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Search macroaxis.com